Xencor, Inc.
Heterodimeric antibodies that bind CD3 and tumor antigens
Last updated:
Abstract:
The present invention is directed to novel heterodimeric antibodies.
Status:
Grant
Type:
Utility
Filling date:
14 Mar 2019
Issue date:
18 Jan 2022